358 related articles for article (PubMed ID: 22895139)
1. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
Shukuya T; Takahashi T; Kaira R; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Naito T; Kaira K; Murakami H; Endo M; Takahashi K; Yamamoto N
Cancer Sci; 2011 May; 102(5):1032-7. PubMed ID: 21272159
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma.
Toyooka S; Takano T; Kosaka T; Hotta K; Matsuo K; Ichihara S; Fujiwara Y; Soh J; Otani H; Kiura K; Aoe K; Yatabe Y; Ohe Y; Mitsudomi T; Date H
Cancer Sci; 2008 Feb; 99(2):303-8. PubMed ID: 18271929
[TBL] [Abstract][Full Text] [Related]
4. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.
Taniguchi K; Okami J; Kodama K; Higashiyama M; Kato K
Cancer Sci; 2008 May; 99(5):929-35. PubMed ID: 18325048
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib in non small cell lung cancer.
Costanzo R; Piccirillo MC; Sandomenico C; Carillio G; Montanino A; Daniele G; Giordano P; Bryce J; De Feo G; Di Maio M; Rocco G; Normanno N; Perrone F; Morabito A
J Biomed Biotechnol; 2011; 2011():815269. PubMed ID: 21660144
[TBL] [Abstract][Full Text] [Related]
6. Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation.
Miyazawa H; Tanaka T; Nagai Y; Matsuoka M; ; Sutani A; Udagawa K; Zhang J; Hirama T; Murayama Y; Koyama N; Ikebuchi K; Nagata M; Kanazawa M; Nukiwa T; Takenoshita S; Kobayashi K; Hagiwara K
Cancer Sci; 2008 Mar; 99(3):595-600. PubMed ID: 18271876
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non-small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L).
Akamatsu H; Harada H; Tokunaga S; Yoshimura N; Ikeda H; Oizumi S; Sugimoto N; Takano T; Murakami H; Nishimura Y; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2019 Jan; 20(1):e25-e27. PubMed ID: 30266586
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer.
Suzuki R; Hasegawa Y; Baba K; Saka H; Saito H; Taniguchi H; Yamamoto M; Matsumoto S; Kato K; Oishi T; Imaizumi K; Shimokata K
Br J Cancer; 2006 Jun; 94(11):1599-603. PubMed ID: 16670714
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.
Traynor AM; Schiller JH; Stabile LP; Kolesar JM; Eickhoff JC; Dacic S; Hoang T; Dubey S; Marcotte SM; Siegfried JM
Lung Cancer; 2009 Apr; 64(1):51-9. PubMed ID: 18701186
[TBL] [Abstract][Full Text] [Related]
10. Analyzing epidermal growth factor receptor mutation status changes in advanced non-small-cell lung cancer at different sampling time-points of blood within one day.
Wang J; Bai H; Hong C; Wang J; Mei TH
Thorac Cancer; 2017 Jul; 8(4):312-319. PubMed ID: 28437026
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer.
Pallis AG; Fennell DA; Szutowicz E; Leighl NB; Greillier L; Dziadziuszko R
Br J Cancer; 2011 Jun; 105(1):1-8. PubMed ID: 21654681
[TBL] [Abstract][Full Text] [Related]
12. Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer.
Gerber DE; Hamann HA; Rasco DW; Woodruff S; Lee SJ
Patient Educ Couns; 2012 Oct; 89(1):102-8. PubMed ID: 22632736
[TBL] [Abstract][Full Text] [Related]
13. Management of patients with advanced non-small cell lung cancer: role of gefitinib.
Velcheti V; Morgensztern D; Govindan R
Biologics; 2010 May; 4():83-90. PubMed ID: 20531966
[TBL] [Abstract][Full Text] [Related]
14. Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer.
Wilson C; Danson SJ
Lung Cancer (Auckl); 2010; 1():37-51. PubMed ID: 28210105
[TBL] [Abstract][Full Text] [Related]
15. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
Goto K; Nishio M; Yamamoto N; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Fukuyama T; Tamura T
Lung Cancer; 2013 Oct; 82(1):109-14. PubMed ID: 23910906
[TBL] [Abstract][Full Text] [Related]
16. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Sequist LV; Yang JC; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater SL; Orlov S; Tsai CM; Boyer M; Su WC; Bennouna J; Kato T; Gorbunova V; Lee KH; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M
J Clin Oncol; 2013 Sep; 31(27):3327-34. PubMed ID: 23816960
[TBL] [Abstract][Full Text] [Related]
17. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).
Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Harada M; Yoshizawa H; Kinoshita I; Fujita Y; Okinaga S; Hirano H; Yoshimori K; Harada T; Saijo Y; Hagiwara K; Morita S; Nukiwa T;
Ann Oncol; 2013 Jan; 24(1):54-9. PubMed ID: 22967997
[TBL] [Abstract][Full Text] [Related]
18. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
[TBL] [Abstract][Full Text] [Related]
19. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
Yang JC; Wu YL; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu CP; O'Byrne K; Feng J; Lu S; Huang Y; Geater SL; Lee KY; Tsai CM; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su WC; Lee KH; Kato T; Massey D; Shahidi M; Zazulina V; Sequist LV
Lancet Oncol; 2015 Feb; 16(2):141-51. PubMed ID: 25589191
[TBL] [Abstract][Full Text] [Related]
20. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
Seto T; Kiura K; Nishio M; Nakagawa K; Maemondo M; Inoue A; Hida T; Yamamoto N; Yoshioka H; Harada M; Ohe Y; Nogami N; Takeuchi K; Shimada T; Tanaka T; Tamura T
Lancet Oncol; 2013 Jun; 14(7):590-8. PubMed ID: 23639470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
